Sarah Cavanaugh - Dec 8, 2021 Form 4 Insider Report for Celldex Therapeutics, Inc. (CLDX)

Role
SVP of Corp Affairs & Admin.
Signature
/s/ Sam Martin, attorney-in-fact for Sarah Cavanaugh
Stock symbol
CLDX
Transactions as of
Dec 8, 2021
Transactions value $
-$219,439
Form type
4
Date filed
12/10/2021, 03:03 PM
Previous filing
Nov 3, 2021
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLDX Common Stock Options Exercise $16.7K +1.86K +455.15% $9.02 2.27K Dec 8, 2021 Direct
transaction CLDX Common Stock Options Exercise $56.7K +5.47K +241.32% $10.38 7.73K Dec 8, 2021 Direct
transaction CLDX Common Stock Sale -$293K -7.32K -94.72% $40.00 408 Dec 8, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -1.86K -13.95% $0.00 11.5K Dec 8, 2021 Common Stock 1.86K $9.02 Direct F2
transaction CLDX Incentive Stock Option (Right to Buy) Options Exercise $0 -5.47K -6.51% $0.00 78.5K Dec 8, 2021 Common Stock 5.47K $10.38 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale of the shares of Common Stock were made pursuant to a plan intended to comply with Rule 10b5-1 of the Exchange Act, previously entered into on September 10, 2021.
F2 25% vested on June 13, 2019 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
F3 25% vested on June 18, 2021 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.